Day: April 28, 2020

Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.

Written by Customer Service on April 28, 2020. Posted in Public Companies.

The merger CANNOT be consummated without the approval of EACH of the proposals being voted on at the Special Meeting, including approval of a reverse stock split.LOS ANGELES, April 28, 2020 (GLOBE NEWSWIRE) — Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), is urging its stockholders to vote now on the proposed merger with Qualigen, Inc. (“Qualigen”), a biotechnology company focused on the development of novel therapeutics for the treatment of cancer and infectious disease, as well as the expansion of its flagship FastPack® point-of-care diagnostic platform.“We are urging all of our stockholders to take a few minutes to vote by phone, internet or mail on this important transaction,” said Ritter CEO Andrew J. Ritter. “It’s also important to note that the merger cannot be consummated...

MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call

Written by Customer Service on April 28, 2020. Posted in Public Companies.

Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) —MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter 2020 after the market closes on Tuesday, May 5, 2020. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, May 5, 2020 at 4:30 p.m. ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID 2993147.The listen-only webcast of the conference call can be accessed under “Events & Presentations” in the Investor...

Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity

Written by Customer Service on April 28, 2020. Posted in Public Companies.

– Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact amid COVID-19 pandemic –– Mavrilimumab treatment protocol in COVID-19 pneumonia and hyperinflammation shows evidence of treatment response in all 13 non-ventilated patients dosed –– Preparing registrational development program of mavrilimumab in patients with COVID-19 pneumonia and hyperinflammation –– Phase 2 trial of vixarelimab in prurigo nodularis met primary efficacy endpoint: statistically significant reduction of weekly average WI-NRS at Week 8 –HAMILTON, Bermuda, April 28, 2020 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical...

Primoris Services Corporation Announces Utility Award Valued at $105 Million

Written by Customer Service on April 28, 2020. Posted in Public Companies.

DALLAS, April 28, 2020 (GLOBE NEWSWIRE) — Primoris Services Corporation (NASDAQ Global Select: PRIM) (“Primoris” or “Company”) today announced the renewal of a Master Service Agreement (“MSA”) with a major utility customer with a three year anticipated value of $105 million. The contract was secured by Q3 Contracting, part of the Utilities & Distribution segment. The award is a three-year agreement for the construction and installation of electric cable and natural gas mains and services in the Western region of the U.S.It is estimated that the MSA will generate approximately $35 million per year over the course of the contract. While the agreement does not obligate the customer to award Primoris a specific dollar amount, our discussions and history with the customer form the basis for our anticipated value.ABOUT PRIMORISFounded...

Corning Reports First-Quarter 2020 Results

Written by Customer Service on April 28, 2020. Posted in Public Companies.

CORNING, N.Y. , April 28, 2020 (GLOBE NEWSWIRE) — Corning Incorporated (NYSE: GLW) today announced results for first-quarter 2020.GAAP sales were $2.4 billion; core sales were $2.5 billionGAAP EPS was $(0.16); core EPS was $0.20GAAP net loss was $96 million; core net income was $177 millionThe primary difference between GAAP and core results was non-cash charges related to capacity realignment and cash severance paymentsGiven the economic uncertainty and disruption created by COVID-19, the company is withdrawing its full-year 2020 guidance. In response to the pandemic, the company has been and will continue focusing actions on three core priorities: preserving the financial strength of the company, protecting employees and communities, and delivering on customer commitments.Wendell P. Weeks, chairman and chief executive officer, said:...

Smile Direct Club Granted Patent for SmileShop Retail Concept and Treatment Process As Shops Plan to Reopen

Written by Customer Service on April 28, 2020. Posted in Public Companies.

Ensures no clear aligner competitor will be able to duplicate SDC unique model for 18 yearsCompany puts increased safety measures, social distancing in place to protect customers as locations target rolling reopening datesNASHVILLE, Tenn., April 28, 2020 (GLOBE NEWSWIRE) — SmileDirectClub today announced it has been issued a patent for its SmileShop intellectual property from the United States Patent & Trademark Office (”USPTO”). The patent, U.S. Patent No. 10,636,522, further strengthens the telehealth dentistry pioneer’s efforts to bring affordable, accessible oral care to more people through its unique and innovative teledentistry platform and direct-to-consumer business model. The patent ensures no clear aligner competitor will be able to duplicate SmileDirectClub’s unique model for 18 years.“This patent designation is...

Clearside Biomedical Revises NDA Resubmission Timeline and XIPERE™ Commercial Partnership with Bausch Health

Written by Customer Service on April 28, 2020. Posted in Public Companies.

– Management to Host Webcast and Conference Call Today at 8:30 A.M. ET –ALPHARETTA, Ga., April 28, 2020 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today an update to the XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) New Drug Application (NDA) resubmission timeline and to its commercialization and development partnership with Bausch Health Companies Inc. (“Bausch Health”) and Bausch + Lomb, its leading global eye health business.As previously disclosed, the contract manufacturing organization (CMO) for XIPERE has been completing certain requalification activities within its facility. While these manufacturing...

Quarterly Report January – March 2020

Written by Customer Service on April 28, 2020. Posted in Earnings Releases And Operating Results.

First quarter 2020Net sales were MSEK 2,572 (2,806), which was a reduction by eleven percent organically.Adjusted EBITA was MSEK 81 (113) and the adjusted EBITA margin was 3.1 (4.0) percent.The coronavirus had a very tangible negative effect on net sales and the result in the first quarter and is expected to have a considerably greater negative effect in the second quarter.The Group currently has a good liquidity buffer, both in the form of existing cash as well as unutilized credit lines, that amounts to more than SEK 1.2 billion.The result before tax was MSEK 28 (73).The net result was MSEK 15 (50) or SEK 0.43 (1.40) per share.Operating cash flow was MSEK 356 (390), of which acquisitions were MSEK 0 (-5).In light of the enhanced financial uncertainty due to the outbreak of the coronavirus, and as a precautionary measure, the Board considers...

RedHill Biopharma Strengthens Coverage for Talicia® with Preferred Brand Position on Prime Therapeutics NetResults™ National Formulary

Written by Customer Service on April 28, 2020. Posted in Public Companies.

Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care therapies—H. pylori bacterial infection is a Group 1 carcinogen and the strongest risk factor for gastric cancer; H. pylori affects approximately 35% of the U.S. population—Prime Therapeutics is a pharmacy benefit manager (PBM) serving 23 Blue Cross and Blue Shield Plans and more than 30 million members nationallyTEL-AVIV, Israel and RALEIGH, N.C., April 28, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Prime Therapeutics, a pharmacy benefit manager (PBM) serving 23 Blue Cross and Blue Shield Plans and more than 30 million...

Inspire Medical Systems, Inc. to Report First Quarter 2020 Financial Results on May 5, 2020

Written by Customer Service on April 28, 2020. Posted in Public Companies.

MINNEAPOLIS, April 28, 2020 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the first quarter 2020 after the close of trading on Tuesday, May 5. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.About Inspire Medical SystemsInspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved...

Day: April 28, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals